Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CASI Pharmaceuticals ( (CASI) ) just unveiled an announcement.
On September 2, 2025, CASI Pharmaceuticals announced the appointment of Dr. Barbara Krebs-Pohl as an Independent Director to its Board of Directors. Dr. Krebs-Pohl brings over 27 years of experience in biologics development and strategic partnerships, having played significant roles in major acquisitions in the biotech industry. Her expertise is expected to enhance CASI’s development program for CID-103 and contribute to the company’s strategic growth in developing therapies for organ transplant rejection and autoimmune diseases. This appointment marks a strategic move for CASI as it advances its CID-103 program, aiming to strengthen its position in the biopharmaceutical industry.
The most recent analyst rating on (CASI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.
CASI Pharmaceuticals’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and high leverage. Technical analysis provides some neutral signals, but the valuation remains unattractive due to negative earnings. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases. The company’s primary product, CID-103, is an anti-CD38 monoclonal antibody, which is currently in clinical trials for immune thrombocytopenic purpura and has recently received FDA IND clearance for a study in renal allograft antibody-mediated rejection.
Average Trading Volume: 1,328,607
Technical Sentiment Signal: Sell
Current Market Cap: $35.79M
Find detailed analytics on CASI stock on TipRanks’ Stock Analysis page.